Research ExplorerPublicationsImplementing liquid biopsies into clinical decision making f...

Implementing liquid biopsies into clinical decision making for cancer immunotherapy

Standard

Implementing liquid biopsies into clinical decision making for cancer immunotherapy. / Quandt, Dagmar; Dieter Zucht, Hans; Amann, Arno; Wulf-Goldenberg, Anne; Borrebaeck, Carl; Cannarile, Michael; Lambrechts, Diether; Oberacher, Herbert; Garrett, James; Nayak, Tapan; Kazinski, Michael; Massie, Charles; Schwarzenbach, Heidi; Maio, Michele; Prins, Robert; Wendik, Björn; Hockett, Richard; Enderle, Daniel; Noerholm, Mikkel; Hendriks, Hans; Zwierzina, Heinz; Seliger, Barbara.

In: ONCOTARGET, Vol. 8, No. 29, 18.07.2017, p. 48507-48520.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Quandt, D, Dieter Zucht, H, Amann, A, Wulf-Goldenberg, A, Borrebaeck, C, Cannarile, M, Lambrechts, D, Oberacher, H, Garrett, J, Nayak, T, Kazinski, M, Massie, C, Schwarzenbach, H, Maio, M, Prins, R, Wendik, B, Hockett, R, Enderle, D, Noerholm, M, Hendriks, H, Zwierzina, H & Seliger, B 2017, 'Implementing liquid biopsies into clinical decision making for cancer immunotherapy', ONCOTARGET, vol. 8, no. 29, pp. 48507-48520. https://doi.org/10.18632/oncotarget.17397

APA

Quandt, D., Dieter Zucht, H., Amann, A., Wulf-Goldenberg, A., Borrebaeck, C., Cannarile, M., Lambrechts, D., Oberacher, H., Garrett, J., Nayak, T., Kazinski, M., Massie, C., Schwarzenbach, H., Maio, M., Prins, R., Wendik, B., Hockett, R., Enderle, D., Noerholm, M., ... Seliger, B. (2017). Implementing liquid biopsies into clinical decision making for cancer immunotherapy. ONCOTARGET, 8(29), 48507-48520. https://doi.org/10.18632/oncotarget.17397

Vancouver

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M et al. Implementing liquid biopsies into clinical decision making for cancer immunotherapy. ONCOTARGET. 2017 Jul 18;8(29):48507-48520. https://doi.org/10.18632/oncotarget.17397

Bibtex

@article{3abecf8111d844999b4d49de2442ab74,
title = "Implementing liquid biopsies into clinical decision making for cancer immunotherapy",
abstract = "During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies.Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.",
keywords = "Animals, Biomarkers, Tumor, Clinical Decision-Making, Diagnostic Imaging, Humans, Immunotherapy, Liquid Biopsy, Neoplasms, Journal Article, Review",
author = "Dagmar Quandt and {Dieter Zucht}, Hans and Arno Amann and Anne Wulf-Goldenberg and Carl Borrebaeck and Michael Cannarile and Diether Lambrechts and Herbert Oberacher and James Garrett and Tapan Nayak and Michael Kazinski and Charles Massie and Heidi Schwarzenbach and Michele Maio and Robert Prins and Bj{\"o}rn Wendik and Richard Hockett and Daniel Enderle and Mikkel Noerholm and Hans Hendriks and Heinz Zwierzina and Barbara Seliger",
year = "2017",
month = jul,
day = "18",
doi = "10.18632/oncotarget.17397",
language = "English",
volume = "8",
pages = "48507--48520",
journal = "ONCOTARGET",
issn = "1949-2553",
publisher = "IMPACT JOURNALS LLC",
number = "29",

}

RIS

TY - JOUR

T1 - Implementing liquid biopsies into clinical decision making for cancer immunotherapy

AU - Quandt, Dagmar

AU - Dieter Zucht, Hans

AU - Amann, Arno

AU - Wulf-Goldenberg, Anne

AU - Borrebaeck, Carl

AU - Cannarile, Michael

AU - Lambrechts, Diether

AU - Oberacher, Herbert

AU - Garrett, James

AU - Nayak, Tapan

AU - Kazinski, Michael

AU - Massie, Charles

AU - Schwarzenbach, Heidi

AU - Maio, Michele

AU - Prins, Robert

AU - Wendik, Björn

AU - Hockett, Richard

AU - Enderle, Daniel

AU - Noerholm, Mikkel

AU - Hendriks, Hans

AU - Zwierzina, Heinz

AU - Seliger, Barbara

PY - 2017/7/18

Y1 - 2017/7/18

N2 - During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies.Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.

AB - During the last decade, novel immunotherapeutic strategies, in particular antibodies directed against immune checkpoint inhibitors, have revolutionized the treatment of different malignancies leading to an improved survival of patients. Identification of immune-related biomarkers for diagnosis, prognosis, monitoring of immune responses and selection of patients for specific cancer immunotherapies is urgently required and therefore areas of intensive research. Easily accessible samples in particular liquid biopsies (body fluids), such as blood, saliva or urine, are preferred for serial tumor biopsies.Although monitoring of immune and tumor responses prior, during and post immunotherapy has led to significant advances of patients' outcome, valid and stable prognostic biomarkers are still missing. This might be due to the limited capacity of the technologies employed, reproducibility of results as well as assay stability and validation of results. Therefore solid approaches to assess immune regulation and modulation as well as to follow up the nature of the tumor in liquid biopsies are urgently required to discover valuable and relevant biomarkers including sample preparation, timing of the collection and the type of liquid samples. This article summarizes our knowledge of the well-known liquid material in a new context as liquid biopsy and focuses on collection and assay requirements for the analysis and the technical developments that allow the implementation of different high-throughput assays to detect alterations at the genetic and immunologic level, which could be used for monitoring treatment efficiency, acquired therapy resistance mechanisms and the prognostic value of the liquid biopsies.

KW - Animals

KW - Biomarkers, Tumor

KW - Clinical Decision-Making

KW - Diagnostic Imaging

KW - Humans

KW - Immunotherapy

KW - Liquid Biopsy

KW - Neoplasms

KW - Journal Article

KW - Review

U2 - 10.18632/oncotarget.17397

DO - 10.18632/oncotarget.17397

M3 - SCORING: Review article

C2 - 28501851

VL - 8

SP - 48507

EP - 48520

JO - ONCOTARGET

JF - ONCOTARGET

SN - 1949-2553

IS - 29

ER -